Severe PMS and the mood volatility that comes with it are not a personality trait, a lack of resilience, or an inevitable feature of having a cycle. They are the downstream expression of a hormonal imbalance in the luteal phase of the cycle, most commonly a progesterone-to-estrogen ratio that is insufficient to produce the calming, stabilising neurological effects that adequate progesterone normally provides. The severity of PMS tracks directly with the degree of this imbalance, which is why it tends to worsen during periods of sustained stress and improve meaningfully when the underlying hormonal pattern is addressed. The mood symptoms are real. They have a biochemical explanation. And they respond to intervention aimed at the cause, not just the symptoms.
Track mood, irritability, and emotional reactivity across the full cycle for at least two to three months, noting when symptoms appear relative to your period. A consistent pattern of worsening in the 7 to 14 days before menstruation and improving after it is the clearest indicator of a luteal-phase hormonal driver.
Mood volatility with a consistent cyclical pattern (worse before, better after) is a specific clinical signal pointing to the progesterone-to-estrogen ratio in the luteal phase, which is distinct from general anxiety or stress-related mood changes that are not cycle-linked.
If the pattern is consistent across multiple cycles, functional testing timed to the mid-luteal phase (approximately day 21 of a 28-day cycle) captures progesterone at its expected peak and gives the most informative picture of whether luteal phase insufficiency is present.
The most direct explanation for why progesterone insufficiency produces mood symptoms lies in progesterone's neurological function, which goes well beyond its reproductive role.
Progesterone is converted in the brain to a neurosteroid called allopregnanolone, which is one of the most potent positive modulators of GABA-A receptors in the central nervous system. GABA (gamma-aminobutyric acid) is the primary inhibitory neurotransmitter in the brain: its job is to reduce neuronal excitability, produce a sense of calm, and regulate the stress response by dampening the reactivity of the nervous system to perceived threats or demands.
Allopregnanolone, derived from progesterone, enhances this GABA activity. When progesterone levels are adequate in the luteal phase, allopregnanolone provides a consistent calming effect on the nervous system that helps regulate mood, reduce anxiety, support sleep, and maintain emotional stability in the two weeks between ovulation and menstruation.
When progesterone is insufficient relative to estrogen, allopregnanolone production is correspondingly reduced. The GABA enhancement it normally provides diminishes. The result is a nervous system that is more reactive, less buffered against minor stressors, and less able to return to baseline after an emotional response. This is the neurological basis of the irritability, tearfulness, heightened anxiety, and emotional volatility that characterise severe premenstrual symptoms. It is not a psychological response to "that time of the month." It is a measurable reduction in a calming neurochemical with documented effects on GABA receptor activity.
While insufficient progesterone is the primary driver of PMS mood symptoms, estrogen's effects on serotonin contribute a separate layer to the picture.
Estrogen upregulates serotonin production and increases serotonin receptor sensitivity. In the follicular phase of the cycle, when estrogen is rising toward its pre-ovulation peak, many women notice a corresponding lift in mood, energy, and social motivation. This is partly driven by estrogen's serotonergic effects.
In the luteal phase, when estrogen declines (along with progesterone, though progesterone falls proportionally more significantly in a low-progesterone pattern), the withdrawal of estrogen's serotonin-supporting effects can contribute to mood dipping, low motivation, and a low or flat affect that is distinct from the irritability and anxiety of the progesterone-GABA deficit but often co-exists with it.
The combined picture in the week or two before menstruation, for a woman with a low progesterone-to-estrogen ratio, can include both the heightened reactivity of reduced allopregnanolone and the flat, low mood associated with declining estrogen and serotonin, producing a mood profile that shifts between irritability and tearfulness, or that involves both simultaneously. The relative weighting between these two patterns varies between individuals and between cycles.
The connection between work stress and worsened PMS is not psychological in the sense that stress makes you more sensitive to hormonal changes you would otherwise handle. It is biochemical: cortisol elevation directly suppresses progesterone production through the shared steroidogenic pathway.
When the cortisol demand is high, the pregnenolone pathway preferentially produces cortisol at the expense of progesterone. This reduces the progesterone available for luteal phase production, which reduces allopregnanolone, which reduces GABA activity, which produces more pronounced mood symptoms in the days before menstruation.
This mechanism explains a pattern that many women in yachting recognise once it is named: PMS that is noticeably worse during demanding charter periods and more manageable during quieter seasons or genuine recovery periods. The variation is not in the woman's capacity to cope. It is in the progesterone level, which is being suppressed by the cortisol load of the demanding period and recovering somewhat during lower-demand times.
It also explains why addressing cortisol dysregulation is often the most effective upstream intervention for PMS. Reducing the cortisol load reduces the competitive pressure on the shared pathway, allowing more progesterone to be produced, which increases allopregnanolone, which restores GABA activity, which stabilises mood. The chain of causation runs the full length of this pathway, which is why interventions aimed only at the mood symptoms, without addressing the cortisol picture upstream, tend to produce limited or temporary results.
A contributing factor that intensifies premenstrual mood symptoms, and is often underappreciated, is blood sugar instability in the luteal phase.
Progesterone has a mild insulin-desensitising effect: in the second half of the cycle, cells are somewhat less responsive to insulin's glucose uptake signal, which means blood sugar can become less stable and more prone to the peaks and crashes that produce energy dips, carbohydrate cravings, and irritability. In a woman with already elevated cortisol (which also promotes insulin resistance), this luteal phase instability compounds what cortisol is already doing to blood sugar regulation, producing more pronounced swings.
Blood sugar instability does not cause PMS on its own, but it amplifies the mood sensitivity that the progesterone-GABA deficit creates. Irritability that might be manageable in a state of stable blood sugar can become more intense and harder to regulate when it is compounded by a post-lunch energy crash or an afternoon of unmet hunger. In a working environment where crew often eat on schedules driven by guests rather than their own hunger signals, this blood sugar component can be particularly disruptive.
Stabilising blood sugar in the luteal phase through more frequent eating, prioritising protein and fat over refined carbohydrates when food choices allow, and avoiding extended gaps between meals is one of the more practical immediate measures for managing the intensity of premenstrual mood symptoms, alongside the longer-term work of addressing the underlying hormonal pattern.
PMS is difficult enough to navigate in a working environment that provides flexibility, privacy, and the option to adjust demands around the harder days of the cycle. In yachting, none of those accommodations are typically available.
Guest-facing roles require consistent emotional regulation, warmth, and professional presentation regardless of where a crew member is in her cycle. The high interpersonal demand of life on board, from navigating close-quarters relationships with the crew as well as the guests, provides continuous opportunities for the heightened reactivity of the luteal phase to be activated. There is no quiet room to decompress in, no option to reschedule the difficult interaction, and often no colleague who understands the physiological basis of what is happening rather than reading it as a personality issue.
This is not a reason to accept severe PMS as inevitable. It is a reason to take the underlying hormonal pattern seriously, because in this specific working context, the cost of unaddressed premenstrual mood symptoms is higher than it would be in a more forgiving environment. The mood volatility is not a character flaw. It is a solvable hormonal problem, and solving it makes the demands of this work meaningfully more manageable.
PMS was something I normalised for a long time, the way most women in demanding careers do. It was uncomfortable, sometimes more than that, but it was monthly and finite and I managed around it. I didn't think of it as something to investigate. I thought of it as something to get through.
What I understand now, looking at my Pg/E2 ratio across four consecutive panels, is that the low progesterone picture has been consistently present throughout the years I have data for. The mood instability before my period wasn't random and it wasn't about stress sensitivity in some vague, undefined way. It was a predictable expression of insufficient progesterone, which meant insufficient allopregnanolone, which meant less GABA buffering at exactly the point in the cycle when it was most needed.
Since I started tracking properly and addressing the hormonal pattern the data revealed, my PMS has changed significantly. Mood is stable across the cycle in a way it wasn't before. The pain I used to experience is largely gone. That shift did not come from managing the symptoms directly, from pushing through or timing commitments around the difficult days. It came from addressing the hormonal picture underneath them. The data told me what to address. The addressing actually worked.
What I want women in yachting to take from this is that severe PMS and the mood volatility that comes with it are not just part of the deal. They are information. The more demanding the working environment, and the less capacity it offers to withdraw or adapt around a difficult cycle phase, the more important it becomes to address the underlying pattern rather than simply managing the expression of it. You cannot change the charter schedule. You can change the hormonal picture that determines how intensely you experience it.
Premenstrual dysphoric disorder (PMDD) is a more severe form of PMS in which mood symptoms are severe enough to significantly impair daily functioning. The underlying hormonal mechanism is similar, involving progesterone-GABA dynamics and estrogen-serotonin effects, but PMDD involves a heightened neurological sensitivity to normal hormonal fluctuations rather than simply more severe hormonal imbalance. Both conditions benefit from addressing the underlying hormonal pattern, though PMDD may also require additional psychological support. If premenstrual symptoms are significantly impairing your ability to work or function, this is worth discussing with a healthcare provider alongside functional testing.
Yes. The same hormonal imbalance that drives mood volatility also produces physical premenstrual symptoms: bloating and water retention (from estrogen's effects on fluid balance without adequate progesterone to counteract them), breast tenderness, headaches (particularly migraines that correlate with the premenstrual estrogen drop), fatigue, and in some women, significant cramping and pain. Physical and mood symptoms of PMS frequently co-exist because they share a common upstream driver in the progesterone-to-estrogen ratio.
Some forms of hormonal contraception reduce PMS symptoms by suppressing the natural hormonal cycle and replacing it with a synthetic hormone pattern. For some women this is effective symptom management. However, it does not address the underlying cortisol dysregulation that was suppressing progesterone, and it masks the cycle as an ongoing indicator of hormonal function. Whether hormonal contraception is an appropriate choice depends on individual circumstances and priorities, but it is worth understanding that it manages rather than resolves the underlying pattern.
Most women notice meaningful improvement within two to three cycles of targeted intervention, though the full extent of improvement often takes three to six months to become apparent as the hormonal pattern stabilises. Early improvements often include reduced mood reactivity before the period and improved sleep in the luteal phase. Cycle regularity, pain, and more severe mood symptoms typically take somewhat longer to fully resolve. The timeline varies with the duration and severity of the pattern before intervention began.
Several practical measures can reduce the intensity of symptoms within the constraints of vessel life. Stabilising blood sugar by eating protein and fat at regular intervals, particularly in the luteal phase, reduces the blood sugar component of mood instability. Minimising caffeine and alcohol in the week before your period reduces the nervous system reactivity that the reduced GABA buffering of low progesterone leaves you more vulnerable to. Prioritising whatever sleep consistency is available preserves what cortisol regulation is possible. These are management strategies, not solutions, but they can meaningfully reduce the intensity of symptoms while the underlying pattern is being addressed.
Yes, through two main mechanisms. First, certain gut bacteria are responsible for metabolising and clearing excess estrogen from the body. When gut function is compromised, estrogen clearance may be reduced, contributing to the relatively elevated estrogen-to-progesterone ratio that drives PMS. Second, gut health affects the production and availability of serotonin, of which approximately 90 percent is produced in the gut. Compromised gut health can reduce serotonin availability, compounding the serotonergic mood effects of the luteal phase estrogen decline. This gut-hormone connection is explored in more detail in our articles on the gut, hormone and energy connection.
The Crew Vitality Method combines at-home functional lab testing with personalized protocols built for the realities of life in yachting.